IGC Pharma annual ebitda margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma EBITDA Margin Growth & History (IGC)
IGC Pharma's ebitda margin was −853.97% for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | −853.97% | — |
| 2025 · Mar 31 | 2025-03-31 | −537.21% | +143.90 pp |
| 2024 | 2024-03-31 | −681.12% | +516.91 pp |
| 2023 | 2023-03-31 | −1,198.02% | +3915.12 pp |
| 2022 | 2022-03-31 | −5,113.15% | −4194.89 pp |
| 2021 | 2021-03-31 | −918.26% | −753.23 pp |
| 2020 | 2020-03-31 | −165.03% | −75.43 pp |
| 2019 | 2019-03-31 | −89.60% | −8.89 pp |
| 2018 | 2018-03-31 | −80.71% | +204.97 pp |
| 2017 | 2017-03-31 | −285.69% | −251.49 pp |
| 2016 | 2016-03-31 | −34.19% | +12.17 pp |
| 2015 | 2015-03-31 | −46.36% | +33.50 pp |
| 2014 | 2014-03-31 | −79.86% | −57.33 pp |
| 2013 | 2013-03-31 | −22.54% | +132.60 pp |
| 2012 | 2012-03-31 | −155.14% | +215.54 pp |
| 2011 | 2011-03-31 | −370.68% | — |
IGC Pharma quarterly ebitda margin
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | −1,029.43% | −491.63 pp |
| Q1 2026 · Mar 31 | 2026-03-31 | −757.10% | −375.58 pp |
| Q4 2025 | 2025-12-31 | −8,090.00% | −7420.35 pp |
| Q2 2026 · Sep 30 | 2025-09-30 | −1,455.50% | −1063.51 pp |
| Q1 2026 · Jun 30 | 2025-06-30 | −537.80% | +283.52 pp |
| Q4 2025 | 2025-03-31 | −381.52% | +298.48 pp |
| Q3 2025 | 2024-12-31 | −669.65% | +721.53 pp |
| Q2 2025 | 2024-09-30 | −391.99% | +409.73 pp |
| Q1 2025 | 2024-06-30 | −821.32% | −463.85 pp |
| Q4 2024 | 2024-03-31 | −680.00% | +1653.33 pp |
| Q3 2024 | 2023-12-31 | −1,391.18% | −756.84 pp |
| Q2 2024 | 2023-09-30 | −801.72% | +345.81 pp |
| Q1 2024 | 2023-06-30 | −357.48% | +887.81 pp |
| Q4 2023 | 2023-03-31 | −2,333.33% | +42923.81 pp |
| Q3 2023 | 2022-12-31 | −634.34% | +928.34 pp |
| Q2 2023 | 2022-09-30 | −1,147.52% | +6325.69 pp |
| Q1 2023 | 2022-06-30 | −1,245.28% | +1400.17 pp |
| Q4 2022 | 2022-03-31 | −45,257.14% | −42016.40 pp |
| Q3 2022 | 2021-12-31 | −1,562.68% | +473.44 pp |
| Q2 2022 | 2021-09-30 | −7,473.21% | −6218.81 pp |
| Q1 2022 | 2021-06-30 | −2,645.45% | −2327.99 pp |
| Q4 2021 | 2021-03-31 | −3,240.74% | +4924.78 pp |
| Q3 2021 | 2020-12-31 | −2,036.11% | −1747.45 pp |
| Q2 2021 | 2020-09-30 | −1,254.40% | −1185.21 pp |
| Q1 2021 | 2020-06-30 | −317.47% | −230.26 pp |
| Q4 2020 | 2020-03-31 | −8,165.52% | −8056.37 pp |
| Q3 2020 | 2019-12-31 | −288.66% | −166.94 pp |
| Q2 2020 | 2019-09-30 | −69.19% | +34.51 pp |
| Q1 2020 | 2019-06-30 | −87.20% | −53.65 pp |
| Q4 2019 | 2019-03-31 | −109.14% | −52.04 pp |
| Q3 2019 | 2018-12-31 | −121.71% | −60.29 pp |
| Q2 2019 | 2018-09-30 | −103.70% | +6.51 pp |
| Q1 2019 | 2018-06-30 | −33.56% | +703.90 pp |
| Q4 2018 | 2018-03-31 | −57.10% | — |
| Q3 2018 | 2017-12-31 | −61.42% | +14.65 pp |
| Q2 2018 | 2017-09-30 | −110.21% | +168.39 pp |
| Q1 2018 | 2017-06-30 | −737.45% | −660.80 pp |
| Q3 2017 | 2016-12-31 | −76.06% | −54.68 pp |
| Q2 2017 | 2016-09-30 | −278.60% | −261.12 pp |
| Q1 2017 | 2016-06-30 | −76.65% | −71.20 pp |
| Q4 2016 | 2016-03-31 | −108.56% | −37.47 pp |
| Q3 2016 | 2015-12-31 | −21.38% | −7.79 pp |
| Q2 2016 | 2015-09-30 | −17.48% | +11.33 pp |
| Q1 2016 | 2015-06-30 | −5.45% | +125.61 pp |
| Q4 2015 | 2015-03-31 | −71.09% | — |
| Q3 2015 | 2014-12-31 | −13.59% | +821.08 pp |
| Q2 2015 | 2014-09-30 | −28.81% | −3.68 pp |
| Q1 2015 | 2014-06-30 | −131.06% | −121.14 pp |
| Q3 2014 | 2013-12-31 | −834.66% | −849.66 pp |
| Q2 2014 | 2013-09-30 | −25.13% | −17.83 pp |
| Q1 2014 | 2013-06-30 | −9.92% | −1.20 pp |
| Q4 2013 | 2013-03-31 | −148.32% | +191.68 pp |
| Q3 2013 | 2012-12-31 | 15.00% | +117.04 pp |
| Q2 2013 | 2012-09-30 | −7.30% | +63.28 pp |
| Q1 2013 | 2012-06-30 | −8.72% | +52.32 pp |
| Q4 2012 | 2012-03-31 | −340.00% | +1319.67 pp |
| Q3 2012 | 2011-12-31 | −102.04% | +110.35 pp |
| Q2 2012 | 2011-09-30 | −70.58% | −29.26 pp |
| Q1 2012 | 2011-06-30 | −61.04% | −22.42 pp |
| Q4 2011 | 2011-03-31 | −1,659.67% | — |
| Q3 2011 | 2010-12-31 | −212.38% | — |
| Q2 2011 | 2010-09-30 | −41.32% | — |
| Q1 2011 | 2010-06-30 | −38.63% | — |
IGC Pharma ebitda margin trends
Between the periods ended 2011-03-31 and 2025-12-31, IGC Pharma's ebitda margin decreased from −370.68% to −853.97%, a change of −483.29 percentage points. The latest reported quarter, Q2 2026 · Jun 30, shows −1,029.43%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗